Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non–Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
PURPOSE: The open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan (SG) versus standard-of-care docetaxel in metastatic non–small cell lung cancer (mNSCLC) with progression on/after platinum-based chemotherapy, anti–PD-(L)1, and targeted treatment for actionable genomic alterations (AGAs). Primary analysis is reported. METHODS: Patients were randomly assigned 1:1 (stratified by histology, best response to last anti–PD-(L)1–containing regimen, and AGA treatment received or not) to SG (one 10 mg/kg intravenous infusion on days 1 and 8) or docetaxel (one 75 mg/m 2 intravenous infusion on day 1) in 21-day cycles. Primary end point was overall survival (OS). Key secondary end points were investigator-assessed progression-free survival (PFS), objective response rate, patient-reported symptom assessment, and safety. RESULTS: In the intention-to-treat population (SG, n = 299; docetaxel, n = 304), 55.4% had one previous line of therapy. Median follow-up was 12.7 months (range, 6.0-24.0). The primary end point was not met. There was a numerical OS improvement for SG versus docetaxel (median, 11.1 v 9.8 months; hazard ratio [HR], 0.84 [95% CI, 0.68 to 1.04]; one-sided P = .0534), consistent across squamous and nonsquamous histologies. Median PFS was 4.1 versus 3.9 months (HR, 0.92 [95% CI, 0.77 to 1.11]). An OS benefit was observed for SG (n = 192) versus docetaxel (n = 191) in mNSCLC nonresponsive to last anti–PD-(L)1–containing regimen (3.5-month median OS increase; HR, 0.75 [95% CI, 0.58 to 0.97]); this was consistent across histologies. Among patients receiving SG and docetaxel, 6.8% and 14.2% discontinued because of treatment-related adverse events (TRAEs), respectively; 1.4% and 1.0%, respectively, had TRAEs leading to death. CONCLUSION: Although statistical significance was not met, OS numerically improved with SG versus docetaxel, which was consistent across histologies. Clinically meaningful improvement in OS was noted in mNSCLC nonresponsive to last anti–PD-(L)1–containing regimen. SG was better tolerated than docetaxel and consistent with its known safety profile, with no new safety signals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
Self-citationGaron, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60845-x · Cited by 1,309
Self-citationTagawa, S. T., Balar, A. V., Petrylak, D. P., Kalebasty, A. R., Loriot, Y., Fléchon, A., Jain, R. K., Agarwal, N., Bupathi, M., Barthelemy, P., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.03489 · Cited by 543
Cited by
Hendriks, L. E. L., Remon, J., Faivre-Finn, C., Garassino, M. C., Heymach, J. V., Kerr, K. M., Tan, D. S. W., Veronesi, G., & Reck, M. (2024) · Nature Reviews Disease Primers · doi:10.1038/s41572-024-00551-9 · Cited by 568
Self-citationNew promises and challenges in the treatment of advanced non-small-cell lung cancer
Meyer, M.-L., Fitzgerald, B. G., Paz-Ares, L., Cappuzzo, F., Jänne, P. A., Peters, S., & Hirsch, F. R. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01029-8 · Cited by 453
Self-citationThe Journey of Antibody–Drug Conjugates: Lessons Learned from 40 Years of Development
Colombo, R., Tarantino, P., Rich, J. R., LoRusso, P. M., & de Vries, E. G. E. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-24-0708 · Cited by 254
Ahn, M.-J., Tanaka, K., Paz-Ares, L., Cornelissen, R., Girard, N., Pons-Tostivint, E., Vicente Baz, D., Sugawara, S., Cobo, M., Pérol, M., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01544 · Cited by 244
“31 These results highlight the challenges of treating this patient population and the need for more effective and tol-erabletreatment options forpatientswho progressafter fi rst-line therapy.”
Self-citationAdvances in molecular pathology and therapy of non-small cell lung cancer
Huang, Q., Li, Y., Huang, Y., Wu, J., Bao, W., Xue, C., Li, X., Dong, S., Dong, Z., & Hu, S. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02243-6 · Cited by 197
Sands, J., Ahn, M.-J., Lisberg, A., Cho, B. C., Blumenschein, G., Shum, E., Pons Tostivint, E., Goto, Y., Yoh, K., Heist, R., et al. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-24-01349 · Cited by 130
Self-citationFang, W., Li, X., Wang, Q., Meng, X., Zheng, W., Sun, L., Yao, W., Zhuang, W., Fan, Y., Zhuo, M., et al. (2025) · BMJ · doi:10.1136/bmj-2025-085680 · Cited by 51
“…evaluated trophoblast cell surface antigen 2 directed antibody-drug conjugates in NSCLC populations with or without actionable genomic alterations, 12 13 the current trial specifically focused on patients with NSCLC and sensitising EGFR mutation with disease progression after EGFR-tyrosine kinase…”
InfluentialLin, Y., Yu, Y., Hu, Z., Wei, C., Wang, Z., Zhang, Y., Wu, Z., Yu, B., Zhao, X., Yu, H., et al. (2026) · Clinical and Translational Medicine · doi:10.1002/ctm2.70814
“11,12 Other modalities, including CEACAM5 ADC, bispecific antibodies and cancer vaccines, are also being explored.”
Metadata
- Authors
- Paz-Ares, L. G., Juan-Vidal, O., Mountzios, G. S., Felip, E., Reinmuth, N., de Marinis, F., Girard, N., Patel, V. M., Takahama, T., Owen, S. P., Reznick, D. M., Badin, F. B., Cicin, I., Mekan, S., Patel, R., Zhang, E., Karumanchi, D., Garassino, M. C., Ahern, E., Chin, V., Della-Fiorentina, S., Jasas, K., Karapetis, C., Long, J., Nott, L., O'Byrne, K., Underhill, C., Greil, R., Hochmair, M., Pircher, A., Demey, W., Germonpré, P., Govaerts, E., Pieters, T., Wener, R., Azambuja, A., Borges, G., Castro, G., Castro, S., Cruz, F., Franke, F., Silva, E., Cheema, P., El-Maraghi, R., Kulkarni, S., Nassabein, R., Owen, S., Audigier Valette, C., Bennouna, J., Chouaid, C., Cortot, A., Couraud, S., Debieuvre, D., Denis, F., Dumont, P., Gervais, R., Girard, N., Giroux Leprieur, E., Guisier, F., Hiret, S., Janicot, H., Lamour, C., Madelaine, J., Marcq, M., Pluquet, E., Louis Pujol, J., Ravoire, M., Sabatini, M., Vergnenegre, A., Bohnet, S., Faehling, M., Janning, M., Laack, E., Reinmuth, N., Rittmeyer, A., Wesseler, C., Baka, S., Fountzilas, G., Katsaounis, P., Kotsakis, A., Mountzios, I., Syrigos, K., Dudnik, J., Carmel, F., Merimsky, O., Nechushtan, H., Sobolev, J., Agustoni, F., Cecilia Bettini, A., Brighenti, M., Cerea, G., De Marinis, F., Grisanti, S., Grossi, F., Luciani, A., Maiello, E., Soto Parra, H., Tassone, P., Tonini, G., Agemi, Y., Azuma, K., Baba, T., Fujita, Y., Ichihara, E., Kasai, T., Kato, T., Kobayashi, H., Kuyama, S., Nishino, K., Oki, M., Okishio, K., Sakamoto, T., Sato, Y., Shinno, Y., Takahama, T., Takayama, K., Watanabe, Y., Yanagitani, N., Zenke, Y., Motola Kuba, D., Daniel Pineda Razo, T., Cornelissen, R., Hendriks, L., Kloover, J., Maas, K., van der Leest, C., Bodnar, L., Karaszewska, B., Mruk, A., Alves, P., Araujo, A., Domingues, I., da Conceicao Fernandes Rodrigues, A., Gil, N., Magalhaes, H., Parente, B., Correa, M., Velez-Cortes, H., Aguilar Hernandez, A., Alonso Calderon, R., Barrera, J., Baz, D., Calles, A., Campelo, M., Carpeno, F., Costa, E., Dols, M., Domine Gomez, M., Fernandez de Sanmamed, M., Font, E., Fuentes, J., Pilar Garrido Lopez, M., Juan Vidal, O., Larriba, J., Martinez, L., Palmero Sanchez, R., Ros Martinez, S., Zugazagoitia Fraile, J., Bilici, A., Cicin, I., Demirci, U., Eralp, Y., Gumus, M., Yazici, O., Baijal, S., Clarke, K., Lim, F., Muthukumar, D., Steele, N., Summers, Y., Abdelaziz, A., Avery, E., Badin, F., Connor, C., Daniel, D., Faridi, A., Fields-Meehan, J., Garassino, M., Gersten, T., Haggstrom, D., Hakimian, D., Houck, W., Illum, H., Keresztes, R., Kurkul, C., Kuzma, C., Lerner, R., Liu, S., Menon, S., Owera, R., Patel, V., Percent, I., Piper, A., Prakash, S., Reznick, D., Rios-Perez, J., Sun, J., Tibayan, R., Traynor, A., Walsh, W., & Wender, D.
- Venue
- Journal of Clinical Oncology
- Published
- 2024-08-20
- Volume
- 42
- Issue
- 24
- Pages
- 2860-2872
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4399218268
- Cited by
- 137
- References
- 4
- FWCI
- 34.96
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.